Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 8Neoplasms 4Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Carcinoid Tumor 3Adenoma, Islet Cell 3Adenocarcinoma, Follicular 3Paraganglioma 2Carcinoma, Medullary 2Carcinoma 2Adenoma 2Pheochromocytoma 1Pancreatic Neuroendocrine Tumour Metastatic 1Pancreatic Neuroendocrine Tumors 1Pancreatic Diseases 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neoplasms, Nerve Tissue 1Neoplasms, Glandular and Epithelial 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Metastatic Digestive System Neuroendocrine Tumor G1 1Gastro-enteropancreatic neuroendocrine tumor 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Digestive System Neuroendocrine Tumor G1 × Sunitinib × Endocrine × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡